(AOF) – Poxel announces the publication of its 2023 annual results “at the end of April 2024” when it was initially scheduled for April 9. The biotech specialist in serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH), cites “the expected conclusion of a transaction by the end of April”. Having made significant progress in its search for additional financing, the company aims, by the end of April, to conclude an agreement relating to the monetization of royalties from sales of its product Twymeeg (Imeglimin) in Japan.
Poxel expects that its financial resources will be sufficient to maintain its operations “until the finalization of this monetization transaction”. The company will communicate its new financial calendar for the month of April 2024, once finalized.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
